Global Neglected Tropical Disease Treatments Markets

1

• Global Neglected Tropical Disease Treatments
  Markets

2
Summary

• The global market for neglected tropical diseases
  should reach 2.6 billion by 2021 from 1.4
  billion in 2016 at a compound annual growth rate
  (CAGR) of 14.1, from 2016 to 2021.
• Report Includes
• An overview of the global markets for tropical
  disease treatments.
• Analyses of global market trends, with data from
  2015, estimates for 2016, and projections of
  compound annual growth rates (CAGRs) through
  2021.
• A look at the total addressable market, an
  indication of the number of people affected, and
  the current shares of key marketed therapies.
• Representations of market shares by geography,
  company, and future outlook.
• Insight on some of the newer drug candidates,
  clinical trials, and their end points.
• Analyses of factors such as increases in
  resistance of vectors to common insecticides,
  increases in rapid diagnostic techniques, and no
  established treatment for newer conditions like
  Zika.
• Profiles of major players in the industry.

3
(No Transcript)
4
Study Goals and Objectives

• The report provides an overview of neglected
  tropical diseases and explores evolving treatment
  options and market opportunities. Market
  deterrents, unmet needs and other factors that
  drive research are also discussed, while patents
  that highlight research priorities and predict
  future trends are analyzed.
• The report examines regions as defined by the
  World Health Organization (WHO) and details
  estimated market size as well as forecasts
  through 2021 by region and disease. It also
  describes the contributions, investments and
  portfolios of some of the key players in this
  domain.

5
Reasons for Doing this Study

• Pharmaceutical companies and research
  institutions prioritize research based on the
  needs of the market. Research and development is
  based on the return on investment dictated by
  market demand and consumer purchasing power.
  While the burden of tropical diseases and their
  unmet needs are huge, investment has been limited
  because the conditions affect communities that
  cannot afford exorbitant healthcare expenses.
• However, with initiatives from organizations like
  the WHO, the Gates Foundation and collaborative
  research platforms like the Drugs for Neglected
  Diseases Initiative (DNDi), pharmaceutical and
  biotechnology players are now working together to
  support drug discovery and development. Due to
  the increased mobility of travelers and cargo,
  tropical diseases are no longer restricted to
  endemic regions and have now emerged in new
  areas, further highlighting the need for
  companies to focus their efforts on these
  debilitating and often deadly conditions.

6

• The morbidity associated with recent outbreaks of
  Ebola and Zika have highlighted the
  unpreparedness of both the industry and
  government in dealing with viruses that were once
  endemic to regions such as Africa. The need for
  drug development for these indications is greater
  than ever and this study provides an overview of
  the collaborations, upcoming product launches and
  other factors driving the market.
• Some of the currently marketed Gold standard
  treatments have started to prove ineffective due
  to the emergence of parasite resistance,
  necessitating the need for the discovery of drugs
  with different mechanisms of action. This report
  includes market intelligence on some of the newer
  candidates in the drug development pipeline,
  listed by disease, as well as patents being filed.

7
Scope of Report

• The report focuses on newer drugs and innovations
  in chemical compounds, vaccines and biologicals
  recently launched or in development. Specifically
  excluded from the scope of research are vector or
  mosquito control approaches, strategies and
  products drugs used for symptomatic treatment
  and not for the elimination of the virus from the
  host and details on manufacturers and suppliers
  of nonbranded generics.
• Products used for diagnosis as well as PCR
  techniques, kits and testing facilities are also
  excluded from the report.
• Research has categorized the markets based on
  regions defined by the WHO since it is the
  primary organization mapping disease prevalence,
  assisting with access to medicine and enabling
  partnerships. Regions include Africa, Americas,
  South-East Asia, Europe, Eastern Mediterranean
  and Western Pacific. These cover all the WHO
  participating countries which are described in
  detail in the subsequent section.

8
Information Sources

• Research conducted a comprehensive literature
  search that included technical newsletters,
  published patent applications, company public
  releases, whitepapers and journals, and several
  other sources. Data were collected through
  interviews and correspondence with key opinion
  leaders in the industry.

9
Methodology

• Both primary and secondary research methodologies
  were used in preparing this study. Projections
  were based on estimates such as disease
  incidence, coverage of vaccine programs and the
  WHOs access to medicine programs.

10
Full Reports
Global Neglected Tropical Disease Treatments
Markets
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Email poonam_at_bharatbook.com O
ur Blog https//www.bharatbook.com/blog/ Twitter
https//twitter.com/researchbook Facebook
https//www.facebook.com/BharatBook3B LinkedIn
http//www.linkedin.com/company/bharat-book-bureau
11

• THANK YOU